Cancer news - the latest biotech news from Labiotech.eu

Home Cancer Page 81

Latest Posts

hsc cancer

News and Trends 13 Sep 2017

Italian Biotech Closes €7M Series B for Stem Cells to Treat Cancer

Genenta Science has raised $8M (€7M) in the Series B fundraising round to continue investigating its use of hematopoietic stem cells to treat cancer. Based in Milan, Genenta can add €7M to the €10M secured in Series A of fundraising. Italian, British and Swiss private investors led the investment, and it will allow the biotech to start a second […]

September 13, 2017 - 2 minutesmins - By Alex Dale

4sc resminostat biliary cancer

News and Trends 13 Sep 2017

Epigenetics Drug Proves Effective in Phase I for Lethal Cancer

4SC’s partner Yakult Honsha has presented positive results at ESMO 2017 for the epigenetics drug resminostat in a Phase I trial run in Japan. The histone deacetylase (HDAC) inhibitor resminostat has shown to induce tumor shrinkage or disease stabilization in all patients with biliary tract cancer in a Phase I trial. The goal was to determine […]

September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

onxeo livatag nanoparticle cancer

News and Trends 12 Sep 2017

French Nanoparticle Therapy Fails to Improve Liver Cancer Treatment in Phase III

Onxeo has announced Phase III results for its nanoparticle chemotherapy Livatag, which failed to improve the outcome for patients with hepatocellular carcinoma compared to other available treatments. The stock of the French oncology specialist Onxeo was halved this morning when it revealed the results of a Phase III trial with its candidate Livatag that failed to […]

September 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

imfinzi astrazeneca breakthrough designation

News and Trends 11 Sep 2017

UPDATE: AstraZeneca’s Checkpoint Inhibitor Could be a Lung Cancer Blockbuster

UPDATE: 11/09/2017: AstraZeneca has presented impressive results at ESMO that show Imfinzi adding 11 months to patient survival, or decreasing the risk of progression by 48%, in Stage 3 NSCLC. This indication represents a sizable market segment — about half of lung cancer — and Imfinzi’s first-line position could make it a blockbuster. Original Publication: […]

September 11, 2017 - 2 minutesmins - By Evelyn Warner

adaptimmune t cells uk

News and Trends 8 Sep 2017

GSK wants in on Adaptimmune’s Adaptable T cell Cancer Treatment

GSK has backed Adaptimmune in the development of their adaptable NY-ESO SPEAR T cell cancer therapy, causing an 11% jump in their premarket value. Adaptimmune has received support from GlaxoSmithKline (GSK) for the development of their NY-ESO SPEAR T cell, which will hopefully treat a range of different cancers. The British pharma giant will pay milestones of up to £48M (€52M) […]

September 8, 2017 - 2 minutesmins - By Alex Dale

Sanofi Regeneron cemiplimab fda

News and Trends 8 Sep 2017

Checkpoint Inhibitor from Regeneron and Sanofi gets Priority After Breakup

The FDA has granted breakthrough therapy designation to Regeneron and Sanofi for cemiplimab, just a month after announcing they will part ways soon. Cemiplimab (REGN2810) has been granted breakthrough therapy designation by the FDA for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), considered the second deadliest skin cancer after melanoma. The antibody is a […]

September 8, 2017 - 1 minutemin - By Clara Rodríguez Fernández

ADVERTISEMENT

cancer peptomyc myc barcelona 1

News and Trends 7 Sep 2017

Spanish Biotech Receives €4.2 Million To Continue Development of Anti-Cancer Peptide

Investment will allow Peptomyc to continue the development of their peptide cancer therapy with reduced side effects. Peptomyc gained €4.2M from a group of investors led by Alta Life Sciences at Series A of fundraising. Peptomyc is part of the growing biotech hub in Barcelona, Spain. A spin-out was formed following research carried out at […]

September 7, 2017 - 2 minutesmins - By Alex Dale

Nucana Biomed Nasdaq IPO Edinburgh

News and Trends 7 Sep 2017

Scottish Oncology Biotech Aims for €96M IPO in the Nasdaq

Nucana Biomed has filed for a Nasdaq IPO in which it expects to raise up to $115M (€96M) to support the progression of its oncology pipeline. Nucana Biomed, a biotech based in Edinburgh, specializes in using phosphoramidate chemistry to upgrade nucleoside analogs, a common form of chemotherapy drugs. With its pipeline reaching late stages of […]

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

viral vectors car t cancer

News and Trends 7 Sep 2017

CAR-T is Nearly Here: How Will It Be Delivered?

As we anticipate the first-ever CAR-T therapy market approval we look at the important aspect of treatment delivery and viral vector strategies. Cell and gene therapy is increasingly coming into its own with some of the major pharma players releasing big headlines. GlaxoSmithKline (GSK) released the first ex vivo stem cell therapy in May 2016 […]

September 7, 2017 - 4 minutesmins - By External Contributor

Merck MSD Rigontec RNA immuno oncology

News and Trends 6 Sep 2017

MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA

MSD is back in the RNA field with the acquisition of Rigontec, a German biotech harnessing RNA interference to make the immune system attack cancer cells. After selling selling Sirna Therapeutics three years ago for almost a tenth of the acquisition price, it seemed like MSD was out of the RNA field. However, the big […]

September 6, 2017 - 1 minutemin - By Clara Rodríguez Fernández

cell medica gregg sando car t

Interview 6 Sep 2017

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

Gilead has just splashed out $12 billion for Kite Pharma, and the FDA is currently reviewing Novartis’ Marketing Approval Application for the first-ever CAR-T therapy. I sat down with Gregg Sando of Cell Medica to hear the perspective of a biotech vying for a piece of the pie. Though he spent 20 years in investment […]

September 6, 2017 - 6 minutesmins - By Evelyn Warner

AMAL Therapeutics Cancer Vaccine Series B

News and Trends 5 Sep 2017

Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines

AMAL Therapeutics has raised €8M to push its colorectal cancer vaccine ATP128 into clinical trials and keep developing its tumor vaccine pipeline. AMAL Therapeutics, a young biotech based in Geneva, is getting a boost for its pipeline of cancer vaccines thanks to a new funding round. The first tranche of its Series B fundraising has gathered €8M (CHF 8.8M) […]

September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

ADVERTISEMENT